Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
BELITE BIO Aktie jetzt für 0€ handeln | |||||
15.09. | Belite Bio: H.C. Wainwright senkt Kursziel auf 98 Dollar aufgrund erhöhter Aktienanzahl | 1 | Investing.com Deutsch | ||
12.09. | Belite Bio completes last subject visit in phase 3 Stargardt trial | 2 | Investing.com | ||
12.09. | Belite Bio, Inc: Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease | 257 | GlobeNewswire (Europe) | Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation... ► Artikel lesen | |
10.09. | Benchmark reiterates Buy rating on Belite Bio stock after $275 million PIPE | 12 | Investing.com | ||
08.09. | Belite Bio sichert sich 125 Millionen Dollar durch Privatplatzierung für Augenmedikamente | 2 | Investing.com Deutsch | ||
08.09. | Belite Bio raises $125 million in private placement for eye disease drugs | 1 | Investing.com | ||
08.09. | Belite Bio, Inc: Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors | 1 | GlobeNewswire (USA) | ||
08.09. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
13.08. | Belite Bio auf H.C. Wainwright Konferenz: Strategischer Fokus auf Augenkrankheiten | 1 | Investing.com Deutsch | ||
12.08. | Belite Bio: Benchmark bekräftigt "Buy"-Rating und Kursziel von 80 US-Dollar | 1 | Investing.com Deutsch | ||
12.08. | Benchmark reiterates Buy rating on Belite Bio stock, maintains $80 price target | 2 | Investing.com | ||
12.08. | Belite Bio targets NDA submission for Tinlarebant in first half of 2026 amid strong cash runway and Phase III progress | 1 | Seeking Alpha | ||
12.08. | Belite Bio Q2 2025 presentation: expenses rise as clinical trials advance | 1 | Investing.com | ||
11.08. | Belite Bio GAAP EPS of -$0.31 beats by $0.10 | 1 | Seeking Alpha | ||
11.08. | Belite Bio, Inc: Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | 262 | GlobeNewswire (Europe) | Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month... ► Artikel lesen | |
08.08. | Belite Bio's Earnings Outlook | 1 | Benzinga.com | ||
07.08. | Belite Bio sichert sich 15 Millionen US-Dollar durch registrierte Direktplatzierung | 1 | Investing.com Deutsch | ||
07.08. | BELITE BIO, INC - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
07.08. | Belite Bio, Inc: Belite Bio Announces Registered Direct Offering of $15 Million | 1 | GlobeNewswire (USA) | ||
03.07. | Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress | 2 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SANGAMO THERAPEUTICS | 0,580 | -2,68 % | SANGAMO THERAPEUTICS, INC - 8-K, Current Report | ||
ARGENX | 678,20 | +0,21 % | Kursgewinne für die Aktie von Argenx (612,60 €) | Im Plus liegt aktuell das Wertpapier von Argenx . Das Papier kostete zuletzt 612,60 Euro. Heute hat sich an der Börse der Anteilsschein von Argenx zwischenzeitlich um 0,62 Prozent verteuert. Der Kurs... ► Artikel lesen | |
AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices Appoints Kenneth Bilenberg as CEO | ||
PROTALIX BIOTHERAPEUTICS | 2,120 | +6,53 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics to Present at Investor Summit Virtual | CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization... ► Artikel lesen | |
ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
QUANTERIX | 6,070 | +7,62 % | Quanterix-Aktionäre stimmen Änderungen bei Verwaltungsrat und Satzung zu | ||
LEXEO THERAPEUTICS | 6,630 | -0,60 % | Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights | Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia... ► Artikel lesen | |
ADMA BIOLOGICS | 14,660 | +0,83 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
CG ONCOLOGY | 39,820 | -0,05 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
ARVINAS | 9,610 | +3,61 % | Arvinas Inc.: Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | ||
IMMUNOME | 12,380 | +7,93 % | Where Immunome Stands With Analysts | ||
JANUX THERAPEUTICS | 24,000 | +3,05 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
ARS PHARMACEUTICALS | 10,310 | +0,19 % | ARS Pharma secures $250M loan to accelerate Neffy rollout |